size-exclusion chromatography is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Testing hydrolysate powders typically begins with proximate analysis for moisture, ash, fat, and total nitrogen. Protein content is calculated from nitrogen using a conversion factor, most often Kjeldahl or Dumas combustion. Peptide size distribution is assessed by size-exclusion chromatography, reversed-phase HPLC, or mass spectrometry. Sodium dodecyl sulfate polyacrylamide gel electrophoresis can show residual intact protein bands. Free amino groups may be quantified by colorimetric assays to estimate cleavage extent, though different methods and laboratories are not always directly comparable.
Dry hydrolysate powders are generally stable when kept cool, dry, and sealed, while moisture uptake can cause caking, Maillard browning, and loss of solubility. Higher temperatures accelerate these changes and may alter flavor. Recommended storage conditions often fall between 15 and 25 degrees Celsius with relative humidity below 60 percent. Once reconstituted, liquid hydrolysate solutions support microbial growth and may develop bitterness or haze over time. Packaging in moisture-barrier containers with desiccants helps maintain quality during transport and warehouse storage.
Quality control for hydrolysate ingredients focuses on identity, purity, and consistency, with specifications that may include total protein, hydrolysis level, molecular weight distribution, microbiological limits, heavy metals, and allergen labeling. In some jurisdictions, partially and extensively hydrolyzed formulas are regulated as foods for special dietary uses or as infant formula ingredients. Regulatory status varies by country and intended use. Documentation such as certificates of analysis, safety data sheets, and method validation records supports traceability. Open questions remain about standardizing hydrolysis measurements across suppliers and laboratories.
Quality control checks identity, composition, and contaminants. Moisture, ash, fat, and carbohydrate are measured by standard methods, and microbiological limits are set for total counts, coliforms, and specific pathogens. Heavy metals and pesticide residues may be monitored depending on market requirements. Adulteration with intact whey protein or individual amino acids is possible, so peptide fingerprints and free amino acid profiles can help verify authenticity. Regulatory frameworks vary: some countries treat hydrolyzed whey as a conventional dairy ingredient, while infant formula uses face additional compositional rules. Which marker peptides best confirm source and processing remains an open analytical question.
Storage stability depends on moisture, temperature, and packaging. Dry powders with low water activity resist microbial growth, but they can still absorb water, develop off-colors through Maillard reactions, or oxidize residual lipids. Sealed containers kept in a cool, dry place are standard. Stability studies typically monitor moisture, solubility, color, peptide size, and microbial counts over months. Established practice favors low humidity and moderate temperatures. How brief excursions above recommended conditions affect peptide profiles and sensory qualities is less predictable and may depend on the specific product matrix.
| Property | Value | Notes |
|---|---|---|
| Moisture content | ≤5% typical | Higher moisture promotes caking and browning |
| pH (5% solution) | 6.0–7.5 typical | Varies with hydrolysis and neutralization |
| Ash content | 1–8% | Depends on demineralization and neutralization salts |
| Microbiological limit | Total aerobic count <10^4 CFU/g typical | Specifications vary by grade and market |
| Shelf life | 12–24 months unopened | Cool, dry storage extends stability |
Degree of hydrolysis is commonly estimated by titrating liberated carboxyl groups, measuring soluble nitrogen in trichloroacetic acid, or using o-phthaldialdehyde assays. Molecular weight distribution is often examined by size-exclusion chromatography, sodium dodecyl sulfate polyacrylamide gel electrophoresis, or mass spectrometry. These methods answer different questions: titration estimates bond cleavage, while chromatography describes peptide size ranges. Because no single reference method is universally applied, values reported by different laboratories may not be directly comparable. Method details such as calibration standards and sample preparation strongly influence results.
Routine quality control for hydrolysate powders includes total nitrogen or protein content by Kjeldahl or Dumas combustion, moisture by oven or Karl Fischer titration, ash, and mineral profiles. Microbiological tests typically cover total aerobic counts, yeasts, molds, and specified pathogens according to regional food safety rules. Amino acid analysis can quantify free amino acids and peptide-bound residues after hydrolysis. For products intended for special populations, additional tests may target residual lactose, fat, or specific allergenic proteins. Specifications are set by the manufacturer and may exceed general food-grade requirements.
Hydrolysate powders are hygroscopic and can absorb moisture during storage, which may promote caking, browning, and loss of solubility. Cool, dry conditions and sealed packaging slow these changes, while high humidity and warm temperatures accelerate Maillard reactions between peptides and residual sugars. Liquid hydrolysates are more perishable and often require refrigeration or preservatives. Shelf-life studies usually monitor moisture, color, solubility, free amino groups, and microbial load over time. Stability depends on residual lactose, water activity, packaging barrier properties, and the initial peptide profile.
Storage stability depends on moisture, temperature, oxygen, and packaging, and hydrolysates are hygroscopic and can cake when exposed to humid air. Maillard reactions between peptides and residual lactose can cause browning and flavor changes during warm storage, while lipid oxidation may develop if residual fat is present. Cool, dry conditions and sealed containers slow these reactions. Shelf-life studies typically monitor moisture, color, solubility, molecular weight profile, and microbial counts over time. Accelerated tests estimate stability, but real-time data remain the reference for shelf-life assignment.
Regulatory status differs by country and intended use. In many jurisdictions, whey protein hydrolysate is regulated as a food ingredient, while specific infant formula or medical food uses may require additional review. Labeling rules govern protein content claims, allergen statements, and terms such as partially hydrolyzed or extensively hydrolyzed. Analytical methods for degree of hydrolysis are not fully standardized, so values can depend on the assay. This variability makes direct comparison between products difficult unless the method and reference material are stated.
Quality control for whey protein hydrolysate begins with specification of protein, moisture, ash, fat, lactose, and degree of hydrolysis, while molecular weight distribution is measured by size-exclusion chromatography or electrophoresis. Free amino acid content can be quantified by amino acid analysis. Microbial limits, heavy metals, and residual enzyme activity are also monitored. Because hydrolysis conditions influence batch consistency, manufacturers validate processes and test each lot against release criteria. Sampling plans and reference standards help compare results across laboratories.
Industrial production begins with whey protein concentrate or isolate dispersed in water. Selected proteases, such as trypsin, pepsin, or microbial enzymes, are added under controlled pH and temperature. Hydrolysis continues until a target hydrolysis level is reached, after which heat or pH adjustment inactivates the enzyme. Ultrafiltration, diafiltration, and ion exchange may remove larger peptides, salts, or residual lactose. The liquid is then concentrated and spray-dried into powder. Processing choices influence peptide size, bitterness, mineral content, and microbial quality.
Analytical control focuses on protein content, hydrolysis extent, molecular weight distribution, and residual intact protein. Kjeldahl or Dumas methods measure total nitrogen, while size-exclusion chromatography or mass spectrometry estimates peptide profiles. Sodium dodecyl sulfate polyacrylamide gel electrophoresis can show remaining intact proteins, though small peptides may not resolve. Enzyme-linked immunosorbent assays are used to assess residual allergenic proteins in some contexts. Because no single method captures all relevant features, manufacturers combine several assays and report values against internal specifications.
Stability depends on moisture, temperature, oxygen, and packaging. Powdered hydrolysate generally requires cool, dry storage and protection from humidity because peptides can absorb water and undergo Maillard reactions with residual lactose. Higher temperatures can increase bitterness, discoloration, and loss of solubility over time, while liquid hydrolysate formats are more perishable and may need refrigeration or preservatives. Shelf-life studies typically monitor moisture, color, pH, protein solubility, and microbial counts. Exact stability limits vary by peptide profile, packaging, and water activity, so general rules should be treated as approximate.
== Extramitochondrial localisation == Cytochrome c is widely believed to be localised solely in the mitochondrial intermembrane space under normal physiological conditions. The release of cytochrome c from mitochondria to the cytosol, where it activates the caspase family of proteases, is believed to be the primary trigger leading to the onset of apoptosis. Measuring the amount of cytochrome c leaking from mitochondria to cytosol, and out of the cell to culture medium, is a sensitive method to monitor the degree of apoptosis. However, detailed immuno-electronmicroscopic studies with rat tissues sections employing cytochrome c specific antibodies provide compelling evidence that cytochrome c under normal cellular conditions is also present at extramitochondrial locations. In pancreatic acinar cells and the anterior pituitary, strong and specific presence of cytochrome c was detected in zymogen granules and in growth hormone granules, respectively. In the pancreas, cytochrome c was also found in condensing vacuoles and in the acinar lumen. The extramitochondrial localisation of cytochrome c was shown to be specific as it was completely abolished upon adsorption of the primary antibody with purified cytochrome c. Besides cytochrome c, extramitochondrial localisation has also been observed for large numbers of other proteins including those encoded by mitochondrial DNA. This raises the possibility of the existence of yet-unidentified specific mechanisms for protein translocation from mitochondria to other cellular destinations.
DNAi – DNA Interactive, including information and Flash clips on RNA Polymerase. RNA+Polymerase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) EC 2.7.7.6 RNA Polymerase – Synthesis RNA from DNA Template (Wayback Machine copy)
In 1948, the Australian psychiatrist John Cade discovered the usefulness of lithium salts in treating mania while working at the Bundoora Repatriation Mental Hospital in Melbourne. He was injecting guinea pigs with urine extracts taken from manic patients in an attempt to isolate a metabolic compound which might be causing mental symptoms. Since uric acid in gout was known to be psychoactive, he needed soluble urate for a control. He used lithium urate, already known to be the most soluble urate compound, and observed that it caused the guinea pigs to become tranquil. Cade traced the effect to the lithium ion itself, and after Cade ingested lithium himself to ensure its safety in humans, he proposed lithium salts as tranquilizers. In 1949, he published his findings in the Medical Journal of Australia in a paper entitled "Lithium salts in the treatment of psychotic excitement". He soon succeeded in controlling mania in chronically hospitalized patients with lithium. This was one of the first successful applications of a drug to treat mental illness, and it opened the door for the development of medicines for other mental problems in the next decades. In 1950, one of Cade's first patients died of lithium toxicity after Cade had successfully treated him and released him from the hospital. Afterward, Cade abandoned the research of lithium and focused instead on testing other salts of rubidium, cerium, and strontium for their potential utility in psychiatry.
=== von Reumont et al. (2012) === In a 2012 molecular study, von Reumont et al. challenge the monophyly of Vericrustacea: they present four versions of Pancrustacea cladogram (figures 1–4), and in all four figures Remipedia is a sister group to Hexapoda, and Branchiopoda is a sister group to (Remipedia + Hexapoda). Thus, their data strongly suggest that Branchiopoda is more closely related to Hexapoda and Remipedia than to Multicrustacea. Based on these data, they propose the following scenario of evolution of Branchiopoda, Remipedia and Hexapoda: under the impact of predatory fishes their common ancestors go to the littoral zone, then ancestors of Branchiopoda go to the ephemeral freshwater habitat, whereas ancestors of Remipedia go to the anchialine cave, and ancestors of Hexapoda go to the land.
Sources: en.wikipedia.org
Excess 129Xe found in carbon dioxide well gases from New Mexico was believed to be from the decay of mantle-derived gases soon after Earth's formation. It has been suggested that the isotopic composition of atmospheric xenon fluctuated prior to the GOE before stabilizing, perhaps as a result of the rise in atmospheric O2.
Insulin efsitora alfa, sold under the brand name Onswik, is an antidiabetic medication used for the treatment of type 2 diabetes. It is a long-acting insulin analog developed by Eli Lilly. Insulin efsitora alfa was authorized for medical use in the European Union in August 2026, and approved for medical use in the United States in September 2026.
=== Snake venom === Although LAAOs are present in a variety of eukaryotic and prokaryotic organisms, snake venom is a particularly rich source of the enzyme and the LAAOs are proposed to supply toxic effects upon envenomation. LAAOs that have been purified from the venoms of various snake species have proven to be the best suitors for examining this novel family of enzymes. It has been determined in most cases concerning the snake families, such as Viperidae, Crotalidae, and Elapidae, that snake venom-LAAO (sv-LAAO) constitutes about 1%–9% of the total protein quantity.
Sources: en.wikipedia.org
It is hypothesized that the various introductions led to multiple genotypes which are adapted to either oaks or conifers. Californian specimens of A. phalloides frequently display yellowish to mustard-yellow caps, a coloration that can closely resemble the edible species Amanita velosa and Amanita calyptroderma, both of which are commonly foraged and consumed in California. This deceptive appearance is the result of environmental homoplasy with Asian cousin Amanita subjunquillea: the fungus expresses a phylogenetically conserved pigment palette (derived from the shikimate pathway) under the particular microclimatic conditions of coastal California oak woodlands. Prolonged high humidity from summer fog drip, followed by intense sunlight and oxidative stress once the fog burns off, upregulates polyphenolic compounds and causes oxidative bleaching of the originally greener or olive tones, producing the characteristic yellowish hues. Such similarity poses a significant risk of fatal misidentification for foragers, as the highly toxic death cap may be mistaken for these otherwise edible look-alikes. A. phalloides were conveyed to new countries across the Southern Hemisphere with the importation of hardwoods and conifers in the late twentieth century. Introduced oaks appear to have been the vector to Australia and South America; populations under oaks have been recorded from Melbourne, Canberra (where two people died in January 2012, of four who were poisoned), Adelaide, and further observed by citizen scientists in Beechworth, Sydney and Albury.
Valve struggled to find a publisher, as many believed Half-Life was too ambitious for a first-time developer. Sierra On-Line signed Valve for a one-game deal as it was interested in making a 3D action game, especially one based on the Quake engine. Sierra gave Valve an advance of around $1 million in exchange for 30% of the revenue and 100% of the intellectual property; the rest of development was funded by Newell and Harrington. Valve first showed Half-Life in early 1997; it was a success at E3 that year, where Valve demonstrated the animation and artificial intelligence. Novel features of the artificial intelligence included fear and pack behavior. Valve aimed for a November 1997 release to compete with Quake II. By September 1997, the team found that, while they had built some innovative aspects in weapons, enemies, and level design, the game was not fun and there was little design cohesion. Playtesting produced "lukewarm" responses. Sierra would not agree to extra funding, so Newell took out a loan to fund additional development to rework the game and delay its release date. Valve took a novel approach of assigning a small team to build a prototype level containing every element in the game and then spent a month iterating on the level. When the rest of the team played the level, which the designer Ken Birdwell described as "Die Hard meets Evil Dead", they agreed to use it as a baseline. The team developed three theories about what made the level fun.
==== Estrogen ==== Estrogens, together, make up a group of primary female sex hormones synthesized in the ovaries. See Estrogen: Brain and behavior for more on the role of estrogen in behavioral endocrinology.
=== Active funds === A few actively managed investment funds have been created which target the megacap segment of the US stock market. They explicitly give their own definitions of the megacap segment when explaining their investment strategies. The Fidelity Mega Cap Stock Fund mutual fund (ticker symbol: FGRTX) defines megacaps as companies "whose market capitalization is similar to [that] of companies in the Russell Top 200 Index or the S&P 100 Index". As of December 31, 2025, the fund had 116 holdings. The Principal US Mega-Cap ETF (Nasdaq: USMC) defines megacaps as companies "with market capitalizations in the top 50th percentile of the S&P 500 Index". As of September 30, 2025, such companies had market caps ranging from $149.6 billion to $4.6 trillion. As of June 30, 2025, the fund had 27 holdings.
Sources: en.wikipedia.org
Keep the powder sealed in a cool, dry place away from direct sunlight and strong odors. Typical targets are 15 to 25 degrees Celsius and low relative humidity. After opening, use within the manufacturer's recommended period.
Size-exclusion chromatography and mass spectrometry provide molecular weight or mass information. Electrophoresis can reveal intact protein bands and larger fragments. No single method captures the complete peptide profile.
Not always, because assays and calculation methods differ. Values may reflect free amino groups, pH change, or nitrogen solubility. Comparisons require method details and reference standards.
Common laboratory methods measure free amino groups with TNBS or OPA reagents. The result is converted to a percentage using a reference standard and a defined protocol. Values are method-dependent, so comparisons require the same assay conditions.